PUBLISHER: DelveInsight | PRODUCT CODE: 2023872
PUBLISHER: DelveInsight | PRODUCT CODE: 2023872
T-cell Malignancies - Market Insights, Epidemiology, and Market Forecast - 2036
T-cell Malignancies Insights and Trends
- According to DelveInsight's analysis, T-cell Malignancies market size was found to be ~USD 1,800 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- T-cell malignancies, encompassing Peripheral T-cell Lymphomas (PTCL) and cutaneous subtypes such as Cutaneous T-cell lymphoma (CTCL), represent a clinically heterogeneous and aggressive group of cancers with generally poorer outcomes than B-cell malignancies.
- In CTCL, about 60% of patients are diagnosed at early Stages (IA/IB), which are typically indolent with near-normal life expectancy. However, ~30% may progress to advanced-stage disease, significantly worsening prognosis.
- PTCL accounting for 10-15% of non-Hodgkin lymphomas in the US, 6.5% in EU and 25% in Japan. Incidence varies by region and subtype, with PTCL-NOS, AITL, and ALCL being the most common. Patients face poor prognosis, high relapse rates, and limited durable treatment options, contributing to significant clinical and quality-of-life burden.
- CHOP remains the standard first-line therapy for PTCL, yet substantial unmet need persists for patients who cannot tolerate cytotoxic chemotherapy. ADCETRIS is the only approved first-line agent, reflecting limited therapeutic progress, while CHOP-based combination strategies have largely failed due to increased toxicity and lack of biologically guided approaches.
- Currently, mechlorethamine (VALCHLOR), bexarotene (TARGRETIN), brentuximab vedotin (ADCETRIS), mogamulizumab (POTELIGEO), denileukin diftitox-cxdl (LYMPHIR), and others are approved therapies available for the treatment of CTCL, offering valuable options for both patients and healthcare providers in managing the disease.
- The approved PTCL treatment landscape is led by agents such as brentuximab vedotin (ADCETRIS; Takeda) in CD30-positive disease, romidepsin (ISTODAX; Bristol Myers Squibb), belinostat (BELEODAQ; Acrotech BioPharma), mogamulizumab (POTELIGEO; Kyowa Kirin), crizotinib (XALKORI; Pfizer), and valemetostat tosilate (EZHARMIA; Daiichi Sankyo) in select subtypes, all of which provide modest, subtype-restricted benefit.
- The lack of reliable, disease-specific biomarkers in Cutaneous T-cell lymphoma leads to delayed and uncertain diagnosis, reliance on repeated biopsies, and suboptimal treatment decisions, highlighting a critical need for biomarkers that enable early detection, accurate differentiation, and more durable, personalized therapy selection.
T-cell Malignancies Market Size and Forecast in the 7MM
- 2025 T-cell Malignancies Market Size: ~USD 1,800 million
- 2036 Projected T-cell Malignancies Market Size: ~USD 3,170 million
- T-cell Malignancies Growth Rate (2026-2036): 5.2% CAGR
DelveInsight's 'T-cell Malignancies - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the T-cell Malignancies, historical and forecasted epidemiology, as well as the T-cell Malignancies market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
The T-cell malignancies market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, T-cell malignancies patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in T-cell malignancies and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.
Key Factors Driving the T-cell Malignancies Market
Rising T-cell Malignancies Incidence
The increasing incidence of T-cell malignancies, particularly among older adults, is a key driver of market expansion. In the US, approximately 15,500 incident cases of T-cell malignancis were reported in 2025, with incidence expected to further increase over the forecast period, driven by an aging population and improved diagnosis through better molecular classification and diagnostic tools.
Rising Opportunities in GGT1-Targeted Therapies
Emerging evidence of PTX-100's superior efficacy and safety over LYMPHIR highlights a growing opportunity for drug developers to focus on therapies targeting GGT1 inhibition.
Robust and diversified pipeline (next-gen & multi-target approaches)
The pipeline is rapidly evolving toward dual-target, multi-antigen, and next-generation therapies, designed to overcome relapse, antigen escape, and durability limitations. These innovations are expected to significantly expand efficacy across heterogeneous tumors and improve long-term outcomes.
T-cell Malignancies Understanding and Treatment Algorithm
T-cell Malignancies Overview and Diagnosis
T cell malignancies encompass a heterogeneous group of diseases, each reflecting a clonal evolution of dysfunctional T cells at various stages of development. T-cell lymphomas comprise approximately 10-15% of all Non-Hodgkin's Lymphomas (NHLs). The main subsets are peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
PTCLs refers to the nodal or systemic T-cell lymphomas and comprises 19 different entities with varying clinical and pathologic presentation including PTCL-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and adult T-cell Leukemia/lymphoma (ATLL), a rare and aggressive T-cell lymphoma linked to human T-cell lymphotropic virus type 1 (HTLV-1). CTCL originates in the skin, including the main subtype's mycosisfungoides (MF) and Sezary syndrome. The various subtypes have distinct pathophysiology and molecular profiles. Beyond this, there is geographic diversity.
Diagnosis of T-cell malignancies involves a stepwise approach integrating clinical evaluation, histopathology, and advanced laboratory testing. The initial step includes assessment of presenting symptoms such as skin lesions in CTCL or lymphadenopathy and systemic symptoms in PTCL. This is followed by tissue biopsy (skin, lymph node, or bone marrow), which remains the gold standard for diagnosis. Immunophenotyping using immunohistochemistry or flow cytometry is then performed to confirm T-cell lineage and characterize antigen expression. Molecular testing, including T-cell receptor (TCR) gene rearrangement and next-generation sequencing, is used to establish clonality and identify relevant mutations. Imaging techniques such as CT or PET-CT scans are further utilized to determine disease extent and staging, while bone marrow evaluation may be required in certain cases.
Current T-cell Malignancies Treatment Landscape
The current treatment of T-cell malignancies is based on a combination of chemotherapy, targeted therapies, immunotherapy, and, in select cases, stem cell transplantation, depending on disease subtype and stage. First-line management for aggressive subtypes such as PTCL typically involves multi-agent chemotherapy (e.g., CHOP-based regimens), while indolent conditions like CTCL may be treated with skin-directed and systemic therapies. Targeted agents such as brentuximab vedotin (ADCETRIS) and mogamulizumab (POTELIGEO) are increasingly used, particularly in relapsed or refractory settings, alongside small molecules including HDAC and PI3K inhibitors. Treatment is highly individualized, with transplantation considered for eligible high-risk or relapsed patients.
T-cell Malignancies Unmet Needs
The section "unmet needs of T-cell malignancies" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.
1. Lack of personalized and effective treatment options in CTCL
2. No established standard of care for relapsed/refractory PTCL patients
3. High relapse rates in first-line chemotherapy
4. Impact of CTCL on patient's quality of life, and others.....
T-cell Malignancies Epidemiology
Key Findings from T-cell Malignancies Epidemiological Analysis and Forecast
- According to DelveInsight's estimates, in 2025, the total number of incident cases of T-cell malignanacies in the 7MM were ~15,500.
- In the US, among type-specific T-cell malignancies, pTCL accounted for the majority of cases (~12,330) in 2025, whereas CTCL represented a smaller share with ~3,100 cases.
- In Japan, the age-specific incident cases of CTCL in 2025 were higher in males (~890 cases), whereas females accounted for a comparatively lower number of cases (~560).
- CTCL represents approximately 2-4% of all non-Hodgkin lymphomas, classifying it as an orphan malignancy. Mycosis fungoides is the predominant subtype, accounting for ~55-65% of CTCL cases. The disease is typically diagnosed in older adults, with a median age at onset of 55-65 years, and around 60-70% of patients present with early-stage disease at diagnosis.
T-cell Malignancies Drug Analysis & Competitive Landscape
The T-cell malignancies drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the T-cell malignancies treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the T-cell malignancies therapeutics market.
Approved Therapies for T-cell Malignancies
Denileukin diftitox (LYMPHIR): Citius Pharmaceuticals
Denileukin diftitox is an IL-2 receptor-directed cytotoxin and designed to direct the cytocidal action of Diphtheria Toxin (DT) to cells that express the IL-2 receptor. After uptake into the cell, the DT fragment is cleaved, and the free DT fragments inhibit protein synthesis, resulting in cell death. It is approved in August 2024 for the treatment of adult patients with relapsed or refractory stage I-III CTCL after at least one prior systemic therapy.
T-cell Malignancies Pipeline Analysis
Duvelisib (COPIKTRA): Secura Bio
Duvelisib (COPIKTRA) is an oral dual PI3K-d/? inhibitor being actively evaluated in clinical development for T-cell malignancies, particularly PTCL. PI3K signaling may lead to the proliferation of malignant cells and is thought to play a role in the formation and maintenance of a supportive tumor microenvironment.
T-cell Malignancies Key Players, Market Leaders and Emerging Companies
- Kyowa Hakko Kirin
- Pfizer (Seagen)
- Takeda
- Helsinn Therapeutics
- Citius Pharmaceuticals
- HUYA Bioscience International (HUYABIO)
- Acrotech Biopharma
- Mundipharma
- Soligenix
- Sterling Pharma Solutions
- Prescient Therapeutics
- Innate Pharma, and others
T-cell Malignancies Drug Updates
- In March 2026, Prescient Therapeutics is advancing enrolment in its Phase II clinical trial for lead asset PTX-100, with new research highlighting steady progress across trial execution, regulatory milestones and funding, while pointing to valuation upside from current levels.
- In December 2025, Corvus Pharmaceuticals announced the presentation of final data from its Phase I/Ib trial of soquelitinib in patients with T-cell lymphoma at ASH 2025. These results provide the foundation for the ongoing registration Phase III trial in r/r PTCL.
- In November 2025, Innate announced that the US FDA has completed its review of the confirmatory Phase III protocol for lacutamab in CTCL, with no further comments, clearing the trial to proceed.
T-cell Malignancies Market Outlook
The T-cell malignancies market is undergoing a progressive transformation, shifting from historically chemotherapy-driven and non-specific immunosuppressive approaches toward targeted and immunotherapy-based treatment paradigms. Established agents such as brentuximab vedotin (ADCETRIS) and mogamulizumab (POTELIGEO) have already demonstrated the clinical value of precision targeting (e.g., CD30 and CCR4), while immune checkpoint inhibitors such as pembrolizumab (KEYTRUDA) have further expanded the role of immuno-oncology in select T-cell lymphoma settings.
Recent years have seen increasing integration of antibody-drug conjugates (ADCs), monoclonal antibodies, and small-molecule targeted therapies, including agents such as duvelisib and crizotinib, which inhibit key oncogenic signaling pathways involved in T-cell proliferation and survival. This diversification of mechanisms reflects a broader shift toward biology-driven treatment strategies, particularly in relapsed or refractory disease where unmet need remains high.
Concurrently, the pipeline is expanding with next-generation immunotherapies and novel targeted agents, including checkpoint inhibitors, anti-KIR and anti-CD47 approaches, and epigenetic modulators, many of which are being evaluated in early- to mid-stage clinical trials. Combination strategies (e.g., ADCs with checkpoint inhibitors) are also being explored to enhance response durability and overcome resistance, signaling a move toward rational combination regimens in future treatment algorithms.
Overall, the T-cell malignancies market is expected to witness steady evolution rather than rapid disruption, driven by incremental innovation, increasing biomarker-driven patient stratification, and improved disease awareness. While the rarity and heterogeneity of T-cell malignancies may limit large-scale clinical development, the continued entry of targeted and immunotherapeutic agents is anticipated in the gradually reshape the treatment landscape across 7MM T-cell maliganancies market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.
- Among the 7MM, the US accounted for the largest market size of T-cell malignanacies. i.e., USD ~1,250 million in 2025.
- In 2036, among all the therapies for T-cell malignancies, the highest revenue is estimated to be generated by brentuximab vedotin (ADCETRIS), in the US.
- The entry of late-stage candidates such as linperlisib, golidocitinib, and PTX-100 are expected to intensify competition in the T-cell malignanices treatment landscape during the latter half of the forecast period.
Drug Class/Insights into Leading Emerging and Marketed Therapies in T-cell Malignancies (2022-2036 Forecast)
The T-cell malignanacies market comprises monoclonal antibodies, ADCs, and small molecules, each targeting types of T-cell Malignancies.
- Monoclonal antibodies: Therapies such as brentuximab vedotin (ADCETRIS), an ADC targeting CD30, and mogamulizumab (POTELIGEO), a CCR4-directed monoclonal antibody, are key approved options in T-cell lymphomas. In addition, immune checkpoint inhibitors like pembrolizumab (KEYTRUDA) target the PD-1 pathway to enhance anti-tumor immunity, while emerging agents such as sugemalimab further expand the immunotherapy landscape.
- Small molecules: This class includes targeted and epigenetic therapies such as crizotinib (XALKORI), tucidinostat (HIYASTA), and duvelisib, which inhibit oncogenic signaling pathways critical for tumor survival. Other treatments like mechlorethamine (VALCHLOR/LEDAGA) provide skin-directed chemotherapy for cutaneous T-cell lymphoma, while emerging agents such as golidocitinib are being developed to further address unmet needs through novel mechanisms of action.
Small molecules defines the core innovation landscape, with radioligand therapies currently commercially validated and small molecules driving pipeline growth.
T-cell Malignancies Drug Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the T-cell Malignancies drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.
The uptake of therapies in T-cell malignancies is expected to vary based on clinical positioning, mechanism of action, and stage of development. Approved therapies such as denileukin diftitox (LYMPHIR) are projected to demonstrate a medium-fast uptake, supported by their established clinical profile, targeted mechanism, and the high unmet need in relapsed or refractory settings.
Emerging therapies such as Lacutamab (IPH4102), PTX-100, and AUTO4 are anticipated to follow a moderate uptake trajectory, reflecting their investigational status and the gradual build-up of clinical evidence, alongside cautious adoption in clinical practice.
Meanwhile, agents like Linperlisib are expected to show a slow-to-medium uptake, as their positioning within the treatment landscape, differentiation from existing therapies, and long-term efficacy and safety data will play a key role in influencing adoption.
Detailed insights of emerging therapies' drug uptake is included in the report
Market Access and Reimbursement of Approved therapies in T-cell Malignancies
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
T-cell Malignancies Therapies Price Scenario & Trends
Pricing and analogue assessment of T-cell malignancies therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most approproiate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.
Pricing of T-cell Malignancies Approved Drugs
Belinostat (BELEODAQ) is administered at a recommended dose of 1,000 mg/m2, delivered as a 30-minute intravenous infusion once daily on Days 1-5 of a 21-day cycle. Based on current pricing and treatment duration, the estimated total cost of therapy is approximately USD 516,556.
Industry Experts and Physician Views for T-cell Malignancies
To keep up with T-cell malignancies market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the T-cell malignancies emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in T-cell malignancies, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the University of Colorado School of Medicine, Padua University Hospital, University College London Hospitals NHS Foundation Trust, and Humboldt-Universitat zu Berlin, etc. were contacted. Their opinion helps understand and validate current and emerging T-cell malignancies therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in T-cell malignancies.
Qualitative Analysis: SWOT and Conjoint Analysis
We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.
In the SWOT analysis of T-cell malignancies, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Scope of the Report:
- The report covers a segment of key events, an executive summary, a descriptive overview of T-cell malignancies, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
- Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
- A detailed review of the T-cell malignancies market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM T-cell malignancies market.
Report Insights
- T-cell Malignancies Patient Population Forecast
- T-cell Malignancies Therapeutics Market Size
- T-cell Malignancies Pipeline Analysis
- T-cell Malignancies Market Size and Trends
- T-cell Malignancies Market Opportunity (Current and forecasted)
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- Artificial Intelligence (AI)-Enabled Market Research Report
- 11-Year Forecast
- T-cell Malignancies Market Outlook (North America, Europe, Asia-Pacific)
- Patient Burden Trends (By Geography)
- T-cell Malignancies Treatment Addressable Market (Tam)
- T-cell Malignancies Competitive Landscape
- T-cell Malignancies Major Companies Insights
- T-cell Malignancies Price Trends and Analogue Assessment
- T-cell Malignancies Therapies Drug Adoption/Uptake
- T-cell Malignancies Therapies Peak Patient Share Analysis
Report Assessment
- T-cell Malignancies Current Treatment Practices
- T-cell Malignancies Unmet Needs
- T-cell Malignancies Clinical Development Analysis
- T-cell Malignancies Emerging Drugs Product Profiles
- T-cell Malignancies Market attractiveness
- T-cell Malignancies Qualitative Analysis (SWOT and conjoint analysis)
FAQs:
Market Insights
- What was the T-cell malignancies market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
- What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
- What can be the future treatment paradigm of T-cell malignancies?
- What are the disease risks, burdens, and unmet needs of T-cell malignancies? What will be the growth opportunities across the 7MM concerning the patient population with T-cell malignancies?
- Who is the major future competitor in the market, and how will the competitors affect their market share?
- What are the current options for the treatment of T-cell malignancies? What are the current guidelines for treating T-cell malignancies in the US, Europe, and Japan?
Reasons to Buy:
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the T-cell malignancies market.
- Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
- Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
- Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
- Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
- This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets withing the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Market Overview at a Glance
- 6.1. Market Share By Early-Stage CTCL Therapies (%) in 2025 in the 7MM
- 6.2. Market Share By Late-Stage CTCL Therapies (%) in 2025 in the 7MM
- 6.3. Market Share By Early-Stage CTCL Therapies (%) in 2036 in the 7MM
- 6.4. Market Share By Late-Stage CTCL Therapies (%) in 2036 in the 7MM
- 6.5. Market Share (%) Distribution By PTCL Therapies in 2025 in the 7MM
- 6.6. Market Share (%) Distribution By PTCL Therapies in 2036 in the 7MM
7. Disease Background and Overview of T-cell Malignancies
- 7.1. Introduction
- 7.2. Classification
- 7.2.1. CTCL
- 7.2.2. PTCL
- 7.3. Symptoms
- 7.4. Stages
- 7.5. Pathogenesis
- 7.5.1. Molecular Pathogenesis of CTCL
- 7.5.2. Molecular Pathogenesis of PTCL
- 7.6. Diagnosis
8. Treatment of T-cell Malignancies
- 8.1. Treatment of Limited-Stage Mycosis Fungoides/Sezary Syndrome
- 8.2. Treatment of Advanced-Stage Mycosis Fungoides/Sezary Syndrome
- 8.3. Current Treatment Approach For PTCL
- 8.4. Relapsed and Refractory Disease Option
- 8.5. Treatment Guidelines
- 8.5.1. National Comprehensive Cancer Network (NCCN): Guidelines (2025)
- 8.5.1.1. General Considerations For Treatment of Patients with Mycosis Fungoides and Sezary Syndrome
- 8.5.1.2. Supportive Care For Patients with Mycosis Fungoides and Sezary Syndrome
- 8.5.1.3. Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders
- 8.5.1.4. PTCL
- 8.5.2. ESMO Clinical Practice Guidelines For Diagnosis, Treatment
- 8.5.2.1. CTCL: ESMO Clinical Practice Guidelines For Diagnosis, Treatment, and Follow-Up (2018)
- 8.5.2.2. PTCL: ESMO and European Hematology Association (EHA) Management Guidelines
- 8.5.3. British Association of Dermatologists and UK Cutaneous Lymphoma Group Guidelines For The Management of Primary Cutaneous Lymphomas (2018)
- 8.5.4. European Organization For Research and Treatment ff Cancer Recommendations For The Treatment of Mycosis Fungoides/Sezary Syndrome (2023)
- 8.5.5. Japanese Skin Cancer Society Guidelines For The Management of Primary Cutaneous Lymphomas (2020)
- 8.5.1. National Comprehensive Cancer Network (NCCN): Guidelines (2025)
9. Epidemiology and Patient Population of T-cell Malignancies
- 9.1. Key Findings
- 9.2. Total Incident Cases of T-cell Malignancies in the 7MM
- 9.2.1. Total Incident Cases of CTCL in the 7MM
- 9.2.2. Total Incident Cases of PTCL in the 7MM
- 9.3. CTCL Patient Burden
- 9.3.1. Assumptions and Rationale
- 9.3.2. The United States
- 9.3.2.1. Total Incident Cases of CTCL in the United States
- 9.3.2.2. Type-specific Cases of CTCL in the United States
- 9.3.2.3. Gender-specific Cases of CTCL in the United States
- 9.3.2.4. Stage-specific Cases of CTCL in the United States
- 9.3.2.5. Treatment-Eligible Pool For Early and Advanced Stages in the United States
- 9.3.3. EU4 and the UK
- 9.3.3.1. Total Incident Cases of CTCL in EU4 and the UK
- 9.3.3.2. Type-specific Cases of CTCL in EU4 and the UK
- 9.3.3.3. Gender-specific Cases of CTCL in EU4 and the UK
- 9.3.3.4. Stage-specific Cases of CTCL in EU4 and the UK
- 9.3.3.5. Treatment-Eligible Pool For Early and Advanced Stages in EU4 and the UK
- 9.3.4. Japan
- 9.3.4.1. Total Incident Cases of CTCL in Japan
- 9.3.4.2. Type-specific Cases of CTCL in Japan
- 9.3.4.3. Gender-specific Cases of CTCL in Japan
- 9.3.4.4. Stage-specific Cases of CTCL in Japan
- 9.3.4.5. Treatment-Eligible Pool For Early and Advanced Stages in Japan
- 9.4. PTCL Patient Burden
- 9.4.1. Assumptions and Rationale
- 9.4.2. The United States
- 9.4.2.1. Total Incident Cases of PTCL in the United States
- 9.4.2.2. Stage-specific Incident Cases of PTCL in the United States
- 9.4.2.3. Subtype-specific Incident Cases of PTCL in the United States
- 9.4.2.4. Line-Wise Treated Cases of PTCL in the United States
- 9.4.3. EU4 and the UK
- 9.4.3.1. Total Incident Cases of PTCL in EU4 and the UK
- 9.4.3.2. Stage-specific Incident Cases of PTCL in EU4 and the UK
- 9.4.3.3. Subtype-specific Incident Cases of PTCL in EU4 and the UK
- 9.4.3.4. Line-Wise Treated Cases of PTCL in EU4 and the UK
- 9.4.4. Japan
- 9.4.4.1. Total Incident Cases of PTCL in Japan
- 9.4.4.2. Stage-specific Incident Cases of PTCL in Japan
- 9.4.4.3. Subtype-specific Incident Cases of PTCL in Japan
- 9.4.4.4. Line-Wise Treated Cases of PTCL in Japan
10. Patient Journey of T-cell Malignancies
11. Marketed Drugs
- 11.1. Marketed Competitive Landscape of CTCL
- 11.2. Marketed Competitive Landscape of PTCL
- 11.3. Mogamulizumab (POTELIGEO): Kyowa Hakko Kirin
- 11.3.1. Product Description
- 11.3.2. Regulatory Milestones
- 11.3.3. Other Developmental Activities
- 11.3.4. Clinical Development
- 11.3.4.1. Clinical Trial Information
- 11.3.5. Summary of Pivotal Trials
- 11.3.6. Safety and Efficacy
- 11.4. Brentuximab Vedotin (ADCETRIS): Pfizer (Seagen) and Takeda
- 11.4.1. Product Description
- 11.4.2. Regulatory Milestones
- 11.4.3. Other Developmental Activities
- 11.4.4. Clinical Development
- 11.4.4.1. Clinical Trials Information
- 11.4.5. Summary of Pivotal Trials
- 11.4.6. Safety and Efficacy
- 11.5. Mechlorethamine (VALCHLOR/LEDAGA): Helsinn Therapeutics
- 11.5.1. Product Description
- 11.5.2. Regulatory Milestones
- 11.5.3. Other Developmental Activities
- 11.5.4. Safety and Efficacy
- 11.6. Denileukin Diftitox (LYMPHIR/REMITORO/E7777/ONTAK): Citius Pharmaceuticals
- 11.6.1. Product Description
- 11.6.2. Regulatory Milestones
- 11.6.3. Other Developmental Activities
- 11.6.4. Summary of Pivotal Trials
- 11.6.5. Safety and Efficacy
- 11.7. Crizotinib (XALKORI): Pfizer
- 11.7.1. Product Description
- 11.7.2. Regulatory Milestones
- 11.7.3. Other Developmental Activities
- 11.7.4. Summary of Pivotal Trials
- 11.8. Tucidinostat (HIYASTA): Huya Bioscience International (Huyabio)
- 11.8.1. Product Description
- 11.8.2. Regulatory Milestones
- 11.8.3. Other Developmental Activities
- 11.8.4. Summary of Pivotal Trials
- 11.9. Darinaparsin (DARVIAS): Solasia Pharma/ Nippon Kayaku
- 11.9.1. Product Description
- 11.9.2. Regulatory Milestones
- 11.9.3. Other Developmental Activities
- 11.9.4. Summary of Pivotal Trials
- 11.1. Pralatrexate (FOLOTYN/DIFOLTA): Acrotech Biopharma/Mundipharma
- 11.10.1. Product Description
- 11.10.2. Regulatory Milestones
- 11.10.3. Other Developmental Activities
- 11.10.4. Summary of Pivotal Trials
- 11.11. Romidepsin (ISTODAX): Bristol Myers Squibb
- 11.11.1. Product Description
- 11.11.2. Regulatory Milestones
- 11.11.3. Other Developmental Activities
- 11.11.4. Summary of Pivotal Trials
- 11.12. Belinostat (BELEODAQ): Acrotech Biopharma
- 11.12.1. Product Description
- 11.12.2. Regulatory Milestones
- 11.12.3. Other Developmental Activities
- 11.12.4. Summary of Pivotal Trials
- 11.13. Forodesine Hydrochloride (MUNDESINE): Mundipharma
- 11.13.1. Product Description
- 11.13.2. Regulatory Milestones
- 11.13.3. Summary of Pivotal Trials
- 11.14. Valemetostat Tosilate (EZHARMIA): Daiichi Sankyo
- 11.14.1. Product Description
- 11.14.2. Regulatory Milestones
- 11.14.3. Other Developmental Activity
- 11.14.4. Clinical Development
- 11.14.4.1. Clinical Trial Information
- 11.14.5. Summary of Pivotal Trials
12. Emerging Therapies
- 12.1. Emerging Competitive Landscape of CTCL
- 12.2. Emerging Competitive Landscape of PTCL
- 12.3. HyBryte (Synthetic Hypericin/SGX301): Soligenix and Sterling Pharma Solutions
- 12.3.1. Product Description
- 12.3.2. Other Developmental Activities
- 12.3.3. Clinical Development
- 12.3.3.1. Clinical Trials Information
- 12.3.4. Safety and Efficacy
- 12.4. PTX-100: Prescient Therapeutics
- 12.4.1. Product Description
- 12.4.2. Other Developmental Activities
- 12.4.3. Clinical Development
- 12.4.3.1. Clinical Trials Information
- 12.4.4. Safety and Efficacy
- 12.5. Lacutamab (IPH4102): Innate Pharma
- 12.5.1. Product Description
- 12.5.2. Other Developmental Activities
- 12.5.3. Clinical Development
- 12.5.3.1. Clinical Trials Information
- 12.5.4. Safety and Efficacy
- 12.6. Linperlisib (YY-20394/Linprixetine): Shanghai Yingli Pharmaceutical
- 12.6.1. Product Description
- 12.6.2. Other Developmental Activity
- 12.6.3. Clinical Development
- 12.6.3.1. Clinical Trial Information
- 12.6.4. Safety and Efficacy
- 12.7. Duvelisib (COPIKTRA): Secura Bio
- 12.7.1. Product Description
- 12.7.2. Other Developmental Activity
- 12.7.3. Clinical Development
- 12.7.3.1. Clinical Trial Information
- 12.7.4. Safety and Efficacy
- 12.8. Golidocitinib (AZD4205/DZD4205): Dizal Pharmaceuticals
- 12.8.1. Product Description
- 12.8.2. Other Developmental Activity
- 12.8.3. Clinical Development
- 12.8.3.1. Clinical Trial Information
- 12.8.4. Safety and Efficacy
- 12.9. Sugemalimab (CEJEMLY/ CS1001): Cstone Pharmaceuticals
- 12.9.1. Product Description
- 12.9.2. Other Developmental Activity
- 12.9.3. Clinical Development
- 12.9.3.1. Clinical Trial Information
- 12.9.4. Safety and Efficacy
- 12.1. Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals
- 12.10.1. Product Description
- 12.10.2. Other Developmental Activities
- 12.10.3. Clinical Development
- 12.10.3.1. Clinical Trials Information
- 12.10.4. Safety and Efficacy
- 12.11. AUTO4: Autolus Therapeutics
- 12.11.1. Product Description
- 12.11.2. Clinical Development
- 12.11.2.1. Clinical Trial Information
- 12.11.3. Safety and Efficacy
- 12.12. Soquelitinib (CPI-818): Corvus Pharmaceuticals
- 12.12.1. Product Description
- 12.12.2. Other Developmental Activity
- 12.12.3. Clinical Development
- 12.12.3.1. Clinical Trial Information
- 12.12.4. Safety and Efficacy
- 12.13. Tambiciclib (GFH009/SLS009): Genfleet Therapeutics/ Sellas Life Sciences
- 12.13.1. Product Description
- 12.13.2. Other Developmental Activity
- 12.13.3. Clinical Development
- 12.13.3.1. Clinical Trial Information
- 12.13.4. Safety and Efficacy
- 12.14. Bosmolisib (BR101801): Boryung Pharmaceutical
- 12.14.1. Product Description
- 12.14.2. Clinical Development
- 12.14.2.1. Clinical Trial Information
- 12.14.3. Safety and Efficacy
13. T-cell Malignancies: 7MM Analysis
- 13.1. Market Outlook
- 13.1.1. CTCL Therapeutic Landscape: Current and Emerging
- 13.1.2. PTCL Therapeutic Landscape: Current and Emerging
- 13.2. Conjoint Analysis
- 13.2.1. CTCL Assessment
- 13.2.2. PTCL Assessment
- 13.3. Key Market Forecast Assumptions
- 13.3.1. Cost Assumptions of CTCL
- 13.3.2. Cost Assumptions of PTCL
- 13.4. Total Market Size of T-cell Malignancies in the 7MM
- 13.4.1. Total Market Size of CTCL in the 7MM
- 13.4.2. Total Market Size of PTCL in the 7MM
- 13.5. CTCL
- 13.5.1. The United States Market Size
- 13.5.1.1. Total Market Size of CTCL in the United States
- 13.5.1.2. Market Size of Early Stage CTCL By Therapies in First-Line in the United States
- 13.5.1.3. Market Size of Early Stage CTCL By Therapies in Second-Line and Above in the United States
- 13.5.1.4. Market Size of Advanced Stage CTCL By Therapies in First-Line in the United States
- 13.5.1.5. Market Size of Advanced Stage CTCL By Therapies n Second-Line and Above in the United States
- 13.5.2. EU4 and the UK Market Size
- 13.5.2.1. Total Market Size of CTCL in EU4 and the UK
- 13.5.2.2. Market Size of Early Stage CTCL By Therapies in First-Line in EU4 and the UK
- 13.5.2.3. Market Size of Early Stage CTCL By Therapies in Second-Line and Above in EU4 and the UK
- 13.5.2.4. Market Size of Advanced Stage CTCL By Therapies in First-Line in EU4 and the UK
- 13.5.2.5. Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in EU4 and the UK
- 13.5.3. Japan
- 13.5.3.1. Total Market Size of CTCL in Japan
- 13.5.3.2. Market Size of Early Stage CTCL By Therapies in First-Line in Japan
- 13.5.3.3. Market Size of Early Stage CTCL By Therapies in Second-Line and Above in Japan
- 13.5.3.4. Market Size of Advanced Stage CTCL By Therapies in First-Line in Japan
- 13.5.3.5. Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in Japan
- 13.5.1. The United States Market Size
- 13.6. PTCL Market Size
- 13.6.1. The United States
- 13.6.1.1. Total Market Size of PTCL in the United States
- 13.6.1.2. Market Size of PTCL By Therapies in the United States
- 13.6.2. EU4 and the UK
- 13.6.2.1. Total Market Size of PTCL in EU4 and the UK
- 13.6.2.2. Market Size of PTCL By Therapies in EU4 and the UK
- 13.6.3. Japan
- 13.6.3.1. Total Market Size of PTCL in Japan
- 13.6.3.2. Market Size of PTCL By Therapies in Japan
- 13.6.1. The United States
14. Unmet Needs of T-cell Malignancies
15. SWOT Analysis of T-cell Malignancies
16. KOL Views of T-cell Malignancies
17. Market Access and Reimbursement
- 17.1. The United States
- 17.1.1. Centre For Medicare and Medicaid Services (CMS)
- 17.2. EU4 and the UK
- 17.2.1. Germany
- 17.2.2. France
- 17.2.3. Italy
- 17.2.4. Spain
- 17.2.5. United Kingdom
- 17.3. Japan
- 17.3.1. MHLW
- 17.4. Market Access and Reimbursement of T-cell Malignancies
18. Appendix
- 18.1. Bibliography
- 18.2. Report Methodology
19. Delveinsight Capabilities
20. Disclaimer
21. About Delveinsight
List of Tables
- Table 1: Summary of T-Cell Malignancies Market and Epidemiology (2022 ? 2036)
- Table 2: Lymphomatoid Papulosis: Histologic Subtypes and Differential Diagnosis
- Table 3: Old and New Who Classifications of PTCLs
- Table 4: Subtypes of PTCL
- Table 5: TMNB Classification For Mycosis Fungoides and Sezary Syndrome
- Table 6: Suggested Regimens: Skin-Directed Therapies
- Table 7: Stage IA Mycosis Fungoides (Limited Skin Involvement Alone; <10% BSA)
- Table 8: Stage IB Mycosis Fungoides (Skin Only Disease With ?10% Bsa) - Stage IIA Mycosis Fungoides
- Table 9: Stage IIB Mycosis Fungoides (Tumor Stage Disease)
- Table 10: Stage III Mycosis Fungoides (Erythrodermic Disease)
- Table 11: Sezary Syndrome (Stage IVA1 Or IVA2)
- Table 12: Stage IV Mycosis Fungoides (Non-Sezary/Visceral Organ Disease) and Mycosis Fungoides With Large Cell Transformation (Mycosis Fungoides-Lct)
- Table 13: Relapsed Or Refractory Disease To Multiple Prior Therapies
- Table 14: First Line Therapy
- Table 15: Second-Line Therapy and Subsequent Therapy (Intention to Proceed with Transplant)
- Table 16: Second-Line Therapy and Subsequent Therapy (No Intention to Transplant)
- Table 17: Second-Line Therapy and Subsequent Therapy (With Intention to Proceed to Transplant)
- Table 18: Second-Line Therapy and Subsequent Therapy (No Intention to Transplant)
- Table 19: Second-Line Therapy and Subsequent Therapy (With Intention to Proceed to Transplant)
- Table 20: Second-Line Therapy and Subsequent Therapy (No Intention To Transplant)
- Table 21: Recommendations For First-Line Treatment of Mycosis Fungoides Stages IA, IB, and IIA
- Table 22: Recommendations For Second-Line Treatment of Mycosis Fungoides Stages IA, IB, and IIA
- Table 23: Recommendations For First-Line Treatment of Mycosis Fungoides Stage IIB
- Table 24: Recommendations For Second-Line Treatment of Mycosis Fungoides Stage IIB
- Table 25: Recommendations For First-Line Treatment of Mycosis Fungoides Stage IIA and B
- Table 26: Recommendations For Second-Line Treatment of Mycosis Fungoides Stage IIIA and B
- Table 27: Recommendations For Treatment of Mycosis Fungoides Stages IVA and IVB
- Table 28: Recommendations For First-Line Treatment of Sezary Syndrome
- Table 29: Recommendations For Second-Line Treatment of Sezary Syndrome
- Table 30: Agents That Can Be Used For Maintenance After Remission Has Been Achieved In Mycosis Fungoides and Sezary Syndrome
- Table 31: Total Incident Cases of T-Cell Malignancies in the 7MM (2022-2036)
- Table 32: Total Incident Cases of CTCL in the 7MM (2022-2036)
- Table 33: Total Incident Cases of PTCL in the 7MM (2022-2036)
- Table 34: Total Incident Cases of CTCL in the US (2022-2036)
- Table 35: Type-specific Cases of CTCL in the US (2022-2036)
- Table 36: Gender-specific CTCL Cases in the US (2022-2036)
- Table 37: Stage-specific Cases of CTCL in the US (2022-2036)
- Table 38: Treatment-Eligible Pool For Early and Advanced Stages in the US (2022-2036)
- Table 39: Total Incident Cases of CTCL in EU4 and the UK (2022-2036)
- Table 40: Type-specific Cases of CTCL in EU4 and the UK (2022-2036)
- Table 41: Gender-specific Cases of CTCL in EU4 and the UK (2022-2036)
- Table 42: Stage-specific Cases of CTCL in EU4 and the UK (2022-2036)
- Table 43: Treatment-Eligible Pool For Early and Advanced Stages in EU4 and the UK (2022-2036)
- Table 44: Total Incident Cases of CTCL in Japan (2022-2036)
- Table 45: Type-Specific Cases of CTCL in Japan (2022-2036)
- Table 46: Gender-Specific CTCL Cases in Japan (2022-2036)
- Table 47: Stage-Specific Cases of CTCL in Japan (2022-2036)
- Table 48: Treatment-Eligible Pool For Early and Advanced Stages in Japan (2022-2036)
- Table 49: Total Incident Cases of PTCL in the US (2022-2036)
- Table 50: Stage-Specific Incident Cases of PTCL in the US (2022-2036)
- Table 51: Subtype-Specific Incident Cases of PTCL in the US (2022-2036)
- Table 52: Line-wise Treated Cases of PTCL in the United States (2022-2036)
- Table 53: Total Incident Cases of PTCL in EU4 and the UK (2022-2036)
- Table 54: Stage-specific Incident Cases of PTCL in Germany (2022-2036)
- Table 55: Stage-specific Incident Cases of PTCL in France (2022-2036)
- Table 56: Stage-specific Incident Cases of PTCL in Italy (2022-2036)
- Table 57: Stage-specific Incident Cases of PTCL in Spain (2022-2036)
- Table 58: Stage-specific Incident Cases of PTCL in The Uk (2022-2036)
- Table 59: Stage-specific Incident Cases of PTCL in EU4 and the UK (2022-2036)
- Table 60: Subtype-specific Incident Cases of PTCL in Germany (2022-2036)
- Table 61: Subtype-specific Incident Cases of PTCL in France (2022-2036)
- Table 62: Subtype-specific Incident Cases of PTCL in Italy (2022-2036)
- Table 63: Subtype-specific Incident Cases of PTCL in Spain (2022-2036)
- Table 64: Subtype-specific Incident Cases of PTCL in the UK (2022-2036)
- Table 65: Subtype-specific Incident Cases of PTCL in EU4 and the UK (2022-2036)
- Table 66: Line-wise Treated Cases of PTCL in Germany (2022-2036)
- Table 67: Line-wise Treated Cases of PTCL in France (2022-2036)
- Table 68 Line-wise Treated Cases of PTCL in Italy (2022-2036)
- Table 69: Line-wise Treated Cases of PTCL in Spain (2022-2036)
- Table 70: Line-wise Treated Cases of PTCL in the UK (2022-2036)
- Table 71: Line-wise Treated Cases of PTCL in EU4 and the UK (2022-2036)
- Table 72: Total Incident Cases of PTCL in Japan (2022-2036)
- Table 73: Stage-specific Incident Cases of PTCL in Japan (2022-2036)
- Table 74: Subtype-specific Incident Cases of PTCL in Japan (2022-2036)
- Table 75: Line-Wise Treated Cases of PTCL in Japan (2022-2036)
- Table 76: Comparison of Marketed Drugs of CTCL
- Table 77: Comparison of Marketed Drugs of PTCL
- Table 78: Mogamulizumab (POTELIGEO), Clinical Trial Description of CTCL, 2026
- Table 79: Brentuximab Vedotin, Clinical Trial Description of PTCL, 2026
- Table 80: Valemetostat Tosilate, Clinical Trial Description, 2026
- Table 81: Comparison of Emerging Drugs Under Development
- Table 82: Comparison of PTCL Emerging Drugs Under Development
- Table 83: HyBryte (Synthetic Hypericin/SGX301), Clinical Trial Description, 2026
- Table 84: PTX-100, Clinical Trial Description, 2026
- Table 85: Lacutamab (IPH4102), Clinical Trial Description of CTCL, 2026
- Table 86: Lacutamab, Clinical Trial Description of PTCL, 2026
- Table 87: Linperlisib, Clinical Trial Description, 2026
- Table 88: Duvelisib, Clinical Trial Description, 2026
- Table 89: Golidocitinib, Clinical Trial Description, 2026
- Table 90: Sugemalimab, Clinical Trial Description, 2026
- Table 91: Tolinapant, Clinical Trial Description, 2026
- Table 92: Auto4, Clinical Trial Description, 2026
- Table 93: Soquelitinib, Clinical Trial Description, 2026
- Table 94: Linperlisib, Clinical Trial Description, 2026
- Table 95: Bosmolisib, Clinical Trial Description, 2026
- Table 96: Key Market Forecast Assumptions of CTCL in the United States
- Table 97: Key Market Forecast Assumptions of CTCL in EU4 and the UK
- Table 98: Key Market Forecast Assumptions of CTCL in Japan
- Table 99: Key Market Forecast Assumptions of PTCL in The United States
- Table 100: Key Market Forecast Assumptions of PTCL in EU4 and the UK
- Table 101: Key Market Forecast Assumptions of PTCL in Japan
- Table 102: Market Size of T-Cell Malignancies in the 7MM, USD million (2020-2034
- Table 103: Market Size of CTCL in the 7MM, USD million (2022-2036)
- Table 104: Market Size of PTCL in the 7MM, USD million (2022-2036)
- Table 105: Market Size of CTCL in the US, USD million (2022-2036)
- Table 106: Market Size of Early Stage CTCL By Therapies in theFirst-Line in the US, USD million (2022-2036)
- Table 107: Market Size of Early Stage CTCL By Therapies in Second-Line and Above in the US, USD million (2022-2036)
- Table 108: Market Size of Advanced Stage CTCL By Therapies in First-Line in the US, USD million (2022-2036)
- Table 109: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in the US, USD million (2022-2036)
- Table 110: Market Size of CTCL By Therapies in the First-Line in the US, USD million (2022-2036)
- Table 111: Market Size of CTCL in EU4 and the UK, USD million (2022-2036)
- Table 112: Market Size of Early Stage CTCL By Therapies in the First-Line in Germany, USD million (2022-2036)
- Table 113: Market Size of Early Stage CTCL By Therapies in the First-Line in France, USD million (2022-2036)
- Table 114: Market Size of Early Stage CTCL By Therapies in the First-Line in Italy, USD million (2022-2036)
- Table 115: Market Size of Early Stage CTCL By Therapies in the First-Line in Spain, USD million (2022-2036)
- Table 116: Market Size of Early Stage CTCL By Therapies in the First-Line in the UK, USD million (2022-2036)
- Table 117: Market Size of Early Stage CTCL By Therapies in the First-Line in EU4 and the UK, USD million (2022-2036)
- Table 118: Market Size of Early Stage CTCL By Therapies in Second-Line and Above in Germany, USD million (2022-2036)
- Table 119: Market Size of Early Stage CTCL By Therapies in Second-Line and Above in France, USD million (2022-2036)
- Table 120: Market Size of Early Stage CTCL By Therapies in Second-Line and Above in Italy, USD million (2022-2036)
- Table 121: Market Size of Early Stage CTCL By Therapies in Second-Line and Above in Spain, USD million (2022-2036)
- Table 122: Market Size of Early Stage CTCL By Therapies in Second-Line and Above in the UK, USD million (2022-2036)
- Table 123: Market Size of Early Stage CTCL By Therapies in Second-Line and Above in EU4 and the UK, USD million (2022-2036)
- Table 124: Market Size of Advanced Stage CTCL By Therapies in First-Line in Germany, USD million (2022-2036)
- Table 125: Market Size of Advanced Stage CTCL By Therapies in First-Line in France, USD million (2022-2036)
- Table 126: Market Size of Advanced Stage CTCL By Therapies in First-Line in Italy, USD million (2022-2036)
- Table 127: Market Size of Advanced Stage CTCL By Therapies in First-Line in Spain, USD million (2022-2036)
- Table 128: Market Size of Advanced Stage CTCL By Therapies in First-Line in the UK, USD million (2022-2036)
- Table 129: Market Size of Advanced Stage CTCL By Therapies in First-Line in EU4 and the UK, USD million (2022-2036)
- Table 130: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in Germany, USD million (2022-2036)
- Table 131: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in France, USD million (2022-2036)
- Table 132: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in Italy, USD million (2022-2036)
- Table 133: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in Spain, USD million (2022-2036)
- Table 134: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in the UK, USD million (2022-2036)
- Table 135: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above In EU4 and the UK, USD million (2022-2036)
- Table 136: Market Size of CTCL in Japan, USD million (2022-2036)
- Table 137: Market Size of Early Stage CTCL By Therapies in the First-Line in Japan, USD million (2022-2036)
- Table 138: Market Size of Early Stage CTCL in Second-Line and Above in Japan, USD million (2022-2036)
- Table 139: Market Size of Advanced Stage CTCL By Therapies in First-Line in Japan, USD million (2022-2036)
- Table 140: Market Size of Advanced Stage CTCL By Therapies in Second-Line and Above in Japan, USD million (2022-2036)
- Table 141: Market Size of PTCL in the US, USD million (2022-2036)
- Table 142: Market Size of PTCL By Therapies in the US, USD million (2022-2036)
- Table 143: Market Size of PTCL in EU4 and the UK, In USD million (2022-2036)
- Table 144: Market Size of PTCL By Therapies in Germany, USD million (2022-2036)
- Table 145: Market Size of PTCL By Therapies in France, USD million (2022-2036)
- Table 146: Market Size of PTCL By Therapies in taly, USD million (2022-2036)
- Table 147: Market Size of PTCL By Therapies in Spain, USD Million (2022-2036)
- Table 148: Market Size of PTCL By Therapies in EU4 and UK, USD Million (2022-2036)
- Table 149: Market Size of PTCL By Therapies in EU4 and the UK, USD Million (2022-2036)
- Table 150: Market Size of PTCL in Japan, USD Million (2022-2036)
- Table 151: Market Size of PTCL By Therapies in Japan, USD Million (2022-2036)
- Table 152: NICE Decisions
- Table 153: IQWIG Assessment
- Table 154: Haute Autorite De Sante (HAS) Decisions
- Table 155: AEMPS Assessment
- Table 156: AIFA Assessment
List of Figures
- Figure 1: Role of Cytokines in the Development of a Th2-biased Inflammatory Milieu Through the Modulation of Chemokines
- Figure 2: Spectrum of Recurrently Mutated Signaling Pathways in CTCL
- Figure 3: Current Frontline Treatment for Common Nodal PTCL
- Figure 4: Frontline Induction Therapy for Common Nodal PTCL
- Figure 5: Treatment Guidelines for Stage IA (Limited Skin Involvement Alone, <10% BSA)
- Figure 6: Treatment Guidelines for Stage IB (skin-only disease with =10% BSA) - Stage IIA
- Figure 7: Treatment Guidelines for Stage IIB (Tumor Stage Disease) Limited Tumor Lesions
- Figure 8: Treatment Guidelines for Stage IIB (tumor stage disease) Generalized Tumor Lesions
- Figure 9: Treatment Guidelines for Stage III (erythrodermic disease)
- Figure 10: Treatment Guidelines for Stage IV
- Figure 11: Treatment Guidelines for Primary Cutaneous ALCL
- Figure 12: Treatment Guideline for Primary Cutaneous ALCL With Regional Node (N1)
- Figure 13: Treatment Guidelines for LyP
- Figure 14: First-line Therapy for PTCL
- Figure 15: Second-line Therapy for PTCL
- Figure 16: Recommendations for the Treatment of Mycosis Fungoides/Sezary Syndrome
- Figure 17: Recommendations for the Initial Management of Primary Cutaneous CD30+ LPDs
- Figure 18: Nodal PTCL
- Figure 19: Extranodal PTCL
- Figure 20: Leukaemia PTCL
- Figure 21: Relapsed/refractory Nodal PTCL
- Figure 22: Relapsed/refractory Extranodal PTCL
- Figure 23: Relapsed/refractory Leukaemia PTCL
- Figure 24: Treatment Algorithm of Mycosis Fungoides
- Figure 25: Treatment Algorithm For Mycosis Fungoides and Sezary Syndrome
- Figure 26: Total Incident cases of T-cell Malignancies in the 7MM (2022-2036)
- Figure 27: Total Incident Cases of CTCL in the 7MM (2022-2036)
- Figure 28: Total Incident cases of PTCL in the 7MM (2022-2036)
- Figure 29: Total Incident Cases of CTCL in the US (2022-2036)
- Figure 30: Type-specific Cases of CTCL in the US (2022-2036)
- Figure 31: Gender-specific CTCL Cases in the US (2022-2036)
- Figure 32: Stage-specific Cases of CTCL in the US (2022-2036)
- Figure 33: Treatment-eligible Pool for Early and Advanced Stages in the US (2022-2036)
- Figure 34: Total Incident Cases of CTCL in EU4 and the UK (2022-2036)
- Figure 35: Type-specific Cases of CTCL in EU4 and the UK (2022-2036)
- Figure 36: Gender-specific Cases of CTCL in EU4 and the UK (2022-2036)
- Figure 37: Stage-specific Cases of CTCL in EU4 and the UK (2022-2036)
- Figure 38: Treatment-eligible Pool for Early and Advanced Stages in EU4 and the UK (2022-2036)
- Figure 39: Total Incident Cases of CTCL in the Japan (2022-2036)
- Figure 40: Type-specific Cases of CTCL in Japan (2022-2036)
- Figure 41: Gender-specific CTCL Cases in Japan (2022-2036)
- Figure 42: Stage-specific Cases of CTCL in Japan (2022-2036)
- Figure 43: Treatment-eligible Pool for Early and Advanced Stages in Japan (2022-2036)
- Figure 44: Total Incident Cases of PTCL in the United States (2022-2036)
- Figure 45: Stage-specific Incident Cases of PTCL in the United States (2022-2036)
- Figure 46: Subtype-specific Incident Cases of PTCL in the United States (2022-2036)
- Figure 48: Line-wise Treated Cases of PTCL in the United States (2022-2036)
- Figure 49: Total Incident Cases of PTCL in EU4 and the UK (2022-2036)
- Figure 50: Stage-specific Incident Cases of PTCL in EU4 and the UK (2022-2036)
- Figure 51: Subtype-specific Incident Cases of PTCL in EU4 and the UK (2022-2036)
- Figure 52: Line-wise Treated Cases of PTCL in EU4 and the UK (2022-2036)
- Figure 53: Total Incident Cases of PTCL in Japan (2022-2036)
- Figure 54: Stage-specific Incident Cases of PTCL in Japan (2022-2036)
- Figure 55: Subtype-specific Incident Cases of PTCL in Japan (2022-2036)
- Figure 56: Line-wise Treated Cases of PTCL in Japan (2022-2036)
- Figure 57: Market Size of T-cell Malignancies in the 7MM, USD million (2022-2036)
- Figure 58: Market Size of CTCL in the 7MM, USD million (2022-2036)
- Figure 59: Market Size of PTCL in the 7MM, USD million (2022-2036)
- Figure 60: Market Size of CTCL in the US, USD million (2022-2036)
- Figure 61: Market Size of Early Stage CTCL by Therapies in the First-line in the US, USD million (2022-2036)
- Figure 62: Market Size of Early Stage CTCL by Therapies in Second-line and above in the US, USD million (2022-2036)
- Figure 63: Market Size of Advanced Stage CTCL by Therapies in First-line in the US, USD million (2022-2036)
- Figure 64: Market Size of Advanced Stage CTCL by Therapies in Second-line and above in the US, USD million (2022-2036)
- Figure 65: Market Size of CTCL in EU4 and the UK, in USD million (2022-2036)
- Figure 66: Market Size of Early Stage CTCL by Therapies in First-line in EU4 and the UK, USD million (2022-2036)
- Figure 67: Market Size of Early Stage CTCL by Therapies In Second-line and above in EU4 and the UK, USD million (2022-2036)
- Figure 68: Market Size of Advanced Stage CTCL by Therapies in First-line, USD million (2022-2036)
- Figure 69 Market Size of Advanced Stage CTCL by Therapies in Second-line and above, USD million (2022-2036)
- Figure 70: Market Size of CTCL in Japan, USD million (2022-2036)
- Figure 71: Market Size of Early Stage CTCL by Therapies in First-line in Japan, USD million (2022-2036)
- Figure 72: Market Size of Early Stage CTCL in Second line in Japan, USD million (2022-2036)
- Figure 73: Market Size of Advanced Stage CTCL by Therapies in First-line in Japan, USD million (2022-2036)
- Figure 74: Market Size of Advanced Stage CTCL in Second-line and above in Japan, USD million (2022-2036)
- Figure 75: Market Size of PTCL in the US, USD million (2022-2036)
- Figure 76: Market Size of PTCL by Therapies in the US, USD million (2022-2036)
- Figure 77: Market Size of PTCL in EU4 and the UK, in USD million (2022-2036)
- Figure 78: Market Size of PTCL by Therapies in EU4 and the UK, USD million (2022-2036)
- Figure 79: Market Size of PTCL in Japan, USD million (2022-2036)
- Figure 80: Market Size of PTCL by Therapies in Japan, USD million (2022-2036)
- Figure 81: Health Technology Assessment
- Figure 82: Reimbursement Process in Germany
- Figure 83: Reimbursement Process in France
- Figure 84: Reimbursement Process in Italy
- Figure 85: Reimbursement Process in Spain
- Figure 86: Reimbursement Process in the United Kingdom
- Figure 87: Reimbursement Process in Japan
